About
AWI Leadership Board
Resources by Tumor Type
Provider Resources
Care Step Pathways
Continuing Education
Provider Toolkits
Healthcare Disparities
Primer
Videos
ctDNA Testing for Response Monitoring
Facebook Provider Community
News
Patient/Caregiver Resources
Patient Action Plans
Caregiver Resource
Options for Stage IV Melanoma
Options for Stage III Melanoma
Options for Stage II Melanoma
Non-Invasive Evaluation Tools (Melanoma)
TIL Therapy
ctDNA Testing Handout
Oncolytic Viruses
International Resources
Australia
Canada
France
Germany
Italy
Portugal
Spain
UK
Videos
HCP Videos
Patient Videos
About
AWI Leadership Board
Resources by Tumor Type
Provider Resources
Care Step Pathways
Continuing Education
Provider Toolkits
Healthcare Disparities
Primer
Videos
ctDNA Testing for Response Monitoring
Facebook Provider Community
News
Patient/Caregiver Resources
Patient Action Plans
Caregiver Resource
Options for Stage IV Melanoma
Options for Stage III Melanoma
Options for Stage II Melanoma
Non-Invasive Evaluation Tools (Melanoma)
TIL Therapy
ctDNA Testing Handout
Oncolytic Viruses
International Resources
Australia
Canada
France
Germany
Italy
Portugal
Spain
UK
Videos
HCP Videos
Patient Videos
The AIM with Immunotherapy Initiative – Home
›
Forums
›
Intralesional immunotherapy
This category has 5 topics, 16 replies, and was last updated
February 11, 2018 at 12:00 am
by
Anonymous
.
Forum
Topics
Posts
Last Post
Expectations for therapy
0
0
No Topics
Dosing and administration
1
3
Reply To: Pharmacy and nurse roles
December 24, 2017 at 4:06 pm
Anonymous
Infectious Precautions
2
9
Reply To: TVEC infection control practices
February 11, 2018 at 12:00 am
Anonymous
Side-effect management
1
8
Reply To: Ocular herpes
January 5, 2018 at 2:54 am
Anonymous
Reimbursement
1
1
December 8, 2017 at 4:58 pm
Other
0
0
No Topics
Login
Log In
Username:
Password:
Keep me signed in
Log In
Register
Lost Password
Latest Activity
New BRAF/MEK inhibitors coming to market
topic by
Anonymous
March 1
in
Dosing and administration
Adjuvant Immunotherapy in stage IIIA patients
topic by
Anonymous
March 1
in
Expectations for therapy
Influenza and Tamiflu and Immunotherapy
reply by
Anonymous
February 25
in
Other
ASCO/NCCN guidlines now out
reply by
Anonymous
February 23
in
Side-effect management
hepatotoxicity
reply by
Anonymous
February 23
in
Side-effect management
Copyright ©2022- - AIM with Immunotherapy. All rights reserved.